Last reviewed · How we verify
Placebo to ERN/LRPT — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo to ERN/LRPT (Placebo to ERN/LRPT) — Merck Sharp & Dohme LLC. This drug is a placebo, meaning it has no active therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo to ERN/LRPT TARGET | Placebo to ERN/LRPT | Merck Sharp & Dohme LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo to ERN/LRPT CI watch — RSS
- Placebo to ERN/LRPT CI watch — Atom
- Placebo to ERN/LRPT CI watch — JSON
- Placebo to ERN/LRPT alone — RSS
Cite this brief
Drug Landscape (2026). Placebo to ERN/LRPT — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-ern-lrpt. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab